Compare AbbVie Inc (ABBV) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Manulife Financial Corporation — how do they compare? AbbVie Inc trades at $253.77 (market cap $449.91B), while Manulife Financial Corporation trades at $41.03 (market cap $68.99B). The key difference: AbbVie Inc is far larger — about 6.5× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| ABBV | MFC | |
|---|---|---|
Market Cap | $449.91B | $68.99B |
Sector | Health | Financials |
52-Week High | $261.07 | $41.40 |
52-Week Low | $184.85 | $29.90 |
Enterprise Value | $513.38B | $65.55B |
Dividend Yield | 2.72% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Manulife Financial (MFC) trades at $41.40, up 0.53% today, with a bullish technical signal from moving averages and strong analyst support (57% buy ratings). Recent Q1 2026 earnings missed expectations, but revenue grew to $53.01B in 2025, with net income of $5.78B. The company maintains a solid dividend, with a $0.49 payment scheduled for June 2026, and has demonstrated consistent operational cash flow growth, reaching $32.11B in 2025.
MFC's outlook is positive due to its AI initiatives and Asia growth, but risks include regulatory scrutiny and Q1 earnings miss. The stock's P/E of 16.92 and ROE of 13.14% suggest reasonable valuation, though investors should monitor debt levels and competitive pressures in insurance markets for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
